SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors

被引:8
|
作者
Qu, D. [1 ]
Yan, A. [1 ]
Zhang, J. S. [2 ]
机构
[1] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing, Peoples R China
[2] Renmin Univ China, High Sch, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Human epidermal growth factor receptor-2 (HER2) inhibitor; structure-activity relationship (SAR); quantitative structure-activity relationship (QSAR); support vector machine (SVM); random forest (RF); multiple linear regression (MLR); ORALLY-ACTIVE INHIBITORS; NEUTRAL; 5-SUBSTITUTED; 4-ANILINOQUINAZOLINES; PYRROLOTRIAZINE DUAL INHIBITORS; TYROSINE KINASE INHIBITORS; BIOLOGICAL EVALUATION; IRREVERSIBLE INHIBITORS; ERBB RECEPTORS; MULTITARGETED INHIBITORS; PYRAZOLINE DERIVATIVES; MOLECULAR DOCKING;
D O I
10.1080/1062936X.2017.1284898
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this paper, structure-activity relationship (SAR, classification) and quantitative structure-activity relationship (QSAR) models have been established to predict the bioactivity of human epidermal growth factor receptor-2 (HER2) inhibitors. For the SAR study, we established six SAR (or classification) models to distinguish highly and weakly active HER2 inhibitors. The dataset contained 868 HER2 inhibitors, which was split into a training set including 580 inhibitors and a test set including 288 inhibitors by a Kohonen's self-organizing map (SOM), or a random method. The SAR models were performed using support vector machine (SVM), random forest (RF) and multilayer perceptron (MLP) methods. Among the six models, SVM models obtained superior results compared with other models. The prediction accuracy of the best model (model 1A) was 90.27% and the Matthews correlation coefficient (MCC) was 0.80 on the test set. For the QSAR study, we chose 286 HER2 inhibitors to establish six quantitative prediction models using MLR, SVM and MLP methods. The correlation coefficient (r) of the best model (model 4B) was 0.92 on the test set. The descriptors analysis showed that HAccN, lone pair electronegativity and electronegativity were closely related to the bioactivity of HER2 inhibitors.
引用
收藏
页码:111 / 132
页数:22
相关论文
共 50 条
  • [21] A gallium telluride quantum dots bioelectrode system for human epidermal growth factor receptor-2 (Her2/neu) oncogene signalling
    Fuku, Xolile
    Singh, Baljit
    Ajayi, Rachel F.
    Jijana, Abongile N.
    Baker, Priscilla
    Dempsey, Eithne
    Iwuoha, Emmanuel
    ANALYTICAL METHODS, 2015, 7 (15) : 6114 - 6124
  • [22] Development of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2)
    Takei, Junko
    Kaneko, Mika
    Ohishi, Tomokazu
    Sayama, Yusuke
    Kawada, Manabu
    Harada, Hiroyuki
    Kato, Yukinari
    CANCER SCIENCE, 2021, 112 : 545 - 545
  • [23] Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
    Siena, S.
    Sartore-Bianchi, A.
    Marsoni, S.
    Hurwitz, H. I.
    McCall, S. J.
    Penault-Llorca, F.
    Srock, S.
    Bardelli, A.
    Trusolino, L.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1108 - 1119
  • [24] Human epidermal growth factor receptor 2 (HER2) expression in urothelial carcinomas of the bladder
    Nalwa, A.
    Elhence, A. B. S. P.
    Bharti, J. Naresh
    Rao, M.
    Choudhary, G. Ram
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S170 - S171
  • [25] Human epidermal growth factor receptor 2 (HER2/neu) supraexpression in the mammary tumors
    Moise, M.
    Motoc, A.
    Raducan, Andreea
    Raducan, S.
    Niculescu, V.
    Niculescu, M.
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2011, 52 (03): : 1101 - 1105
  • [26] Developing a model to predict Human Epidermal Growth Factor Receptor-2 (HER2) expression in Gastric adenocarcinoma based on clinicopathological features: A prospective study
    Subasinghe, Duminda
    Acott, Nathan
    Mahesh, P. K. B.
    Sivaganesh, Sivasuriya
    Samarasekera, Ananthi
    Kumarasinghe, M. P.
    Samarasekera, D. N.
    Lokuhetty, M. D. S.
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 29 - 29
  • [27] Screening Human Epidermal Growth Factor Receptor-2 Inhibitors From Natural Products
    Liu, Xiujie
    Jia, Shaohua
    Dai, Rongji
    Deng, Yulin
    Lv, Fang
    2013 ICME INTERNATIONAL CONFERENCE ON COMPLEX MEDICAL ENGINEERING (CME), 2013, : 497 - 500
  • [28] Inhibition of human epidermal growth factor receptor-2 protein by some alkaloid inhibitors
    Razavi, Leila
    Raissi, Heidar
    JOURNAL OF MOLECULAR LIQUIDS, 2024, 410
  • [29] Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling
    Zalloum, Hiba
    Tayyem, Rabab
    Abu-Irmaileh, Basha'er
    Bustanji, Yasser
    Zihlif, Malek
    Mohammad, Mohammad
    Abu Rjai, Talal
    Mubarak, Mohammad S.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2015, 61 : 61 - 84
  • [30] ASCO/CAP human epidermal growth factor receptor-2 (HER2) in situ hybridization (ISH) categories evaluated by quantitative HER2 protein diagnostic methodologies: A comparative analysis
    Buscaglia, B.
    Turner, B.
    Goda, H.
    Huang, W.
    Leitzel, K.
    Natori, T.
    Nakano, Y.
    Okada, H.
    Sperinde, J.
    Ali, S.
    Vasekar, M.
    D'Aguiar, M.
    McMahon, L.
    Henry, J.
    Lipton, A.
    Hicks, D.
    CANCER RESEARCH, 2019, 79 (04)